We have located links that may give you full text access.
Higher and Sustained Cell-Mediated Immune Responses after Three Doses of mRNA COVID-19 Vaccine In Patients with Inflammatory Bowel Disease on Anti-TNF Therapy.
Clinical and Translational Gastroenterology 2024 Februrary 14
INTRODUCTION: Studies suggest that the generation of durable T cell immunity following COVID-19 vaccination protects against severe disease. The aim of this study was to measure cell mediated immune response (CMIR) one to two months and six months after a third dose of a COVID-19 mRNA vaccine.
METHODS: This prospective study (HERCULES) evaluated CMIR at 28-65 days (t1) after dose 2, 28-65 days (t2) (n=183) and six months (+/-45 days) (t3) (n=167) after a third dose of an mRNA COVID-19 vaccine. A small cohort had blood available 28-65 days (t4) (n=55) after a fourth dose. Primary outcomes were CMIR at (t2) and (t3). Secondary outcomes included the effect of immunosuppressing IBD medications on CMIR and response at (t4).
RESULTS: All patients had measurable CMIR at all time points. CMIR increased at t2 compared to t1 (median 1467 responding cells per million (interquartile range (IQR) 410-5971) vs 313 (94-960) p< 0.001). There was no significant waning when comparing t2 vs t3 or significant boosting at t4. Those on anti-TNF monotherapy had a higher CMIR compared to those not on this therapy at t2 (4132 ( IQR 1136-8795) vs. 869 (IQR 343-3221) p <0.001) and t3 (2843 (IQR 596-6459) vs 654 (IQR 143-2067) p<0.001). In univariable analysis, anti-TNF monotherapy was associated with a higher CMIR at t2 (p< 0.001) and t3 (p< 0.001) and confirmed in a multivariable model (p< 0.001).
CONCLUSION: A third dose of a COVID-19 vaccine boosts CMIR, and the response is sustained in patients with IBD.
METHODS: This prospective study (HERCULES) evaluated CMIR at 28-65 days (t1) after dose 2, 28-65 days (t2) (n=183) and six months (+/-45 days) (t3) (n=167) after a third dose of an mRNA COVID-19 vaccine. A small cohort had blood available 28-65 days (t4) (n=55) after a fourth dose. Primary outcomes were CMIR at (t2) and (t3). Secondary outcomes included the effect of immunosuppressing IBD medications on CMIR and response at (t4).
RESULTS: All patients had measurable CMIR at all time points. CMIR increased at t2 compared to t1 (median 1467 responding cells per million (interquartile range (IQR) 410-5971) vs 313 (94-960) p< 0.001). There was no significant waning when comparing t2 vs t3 or significant boosting at t4. Those on anti-TNF monotherapy had a higher CMIR compared to those not on this therapy at t2 (4132 ( IQR 1136-8795) vs. 869 (IQR 343-3221) p <0.001) and t3 (2843 (IQR 596-6459) vs 654 (IQR 143-2067) p<0.001). In univariable analysis, anti-TNF monotherapy was associated with a higher CMIR at t2 (p< 0.001) and t3 (p< 0.001) and confirmed in a multivariable model (p< 0.001).
CONCLUSION: A third dose of a COVID-19 vaccine boosts CMIR, and the response is sustained in patients with IBD.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app